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OBJECTIVE—To investigate the associations of plasma levels
of soluble receptor for advanced glycation end products
(sRAGE) with incident cardiovascular disease (CVD) and all-
cause mortality in type 1 diabetes and the extent to which any
such associations could be explained by endothelial and renal
dysfunction, low-grade inﬂammation, arterial stiffness, and ad-
vanced glycation end products (AGEs).
RESEARCH DESIGN AND METHODS—We prospectively fol-
lowed 169 individuals with diabetic nephropathy and 170 indi-
viduals with persistent normoalbuminuria who were free of CVD
at study entry and in whom levels of sRAGE and other biomar-
kers were measured at baseline. The median follow-up duration
was 12.3 years (7.6–12.5).
RESULTS—The incidence of fatal and nonfatal CVD and all-
cause mortality increased with higher baseline levels of log-
transformed sRAGE (Ln-sRAGE) independently of other CVD
risk factors: hazard ratio (HR) 1.90 (95% CI 1.13–3.21) and 2.12
(1.26–3.57) per 1-unit increase in Ln-sRAGE, respectively. Adjust-
ments for estimated glomerular ﬁltration rate (eGFRMDRD), but
not or to a smaller extent for markers of endothelial dysfunction,
low-grade inﬂammation, arterial stiffness, and AGEs, attenuated
these associations to HR 1.59 (95% CI 0.91–2.77) for fatal and
nonfatal CVD events and to 1.90 (1.09–3.31) for all-cause mortal-
ity. In addition, in patients with nephropathy, the rate of decline
of GFR was 1.38 ml/min/1.73 m
2 per year greater per 1-unit
increase of Ln-sRAGE at baseline (P  0.036).
CONCLUSIONS—Higher levels of sRAGE are associated with
incident fatal and nonfatal CVD and all-cause mortality in indi-
viduals with type 1 diabetes. sRAGE-associated renal dysfunc-
tion may partially explain this association. Diabetes 59:2027–
2032, 2010
R
ecent studies have suggested a potential role of
the receptor for advanced glycation end prod-
ucts (RAGE) in the development of vascular
disease in individuals with diabetes (1). At the
molecular level, RAGE is upregulated in atherosclerotic
lesions in diabetes (2). RAGE-induced production of ad-
hesion molecules (3–5) and inﬂammatory cytokines (4)
could contribute to endothelial (4,5) and renal dysfunction
(6), low-grade inﬂammation (4,5), and arterial stiffening,
all of which may partially explain the increased cardiovas-
cular disease (CVD) in diabetes.
We have recently shown, in a large cross-sectional study
of type 1 diabetes (EURODIAB), that plasma levels of
sRAGE were positively associated with macro- and micro-
vascular complications, and also with endothelial and
renal dysfunction, and low-grade inﬂammation as patho-
physiological mechanisms that explained in part the asso-
ciations of sRAGE with vascular complications (7).
Whether sRAGE is associated with incident fatal and
nonfatal CVD as well as all-cause mortality in individuals
with type 1 diabetes has never been investigated. In
addition, the extent to which any such associations could
be explained by markers of endothelial and renal dysfunc-
tion, low-grade inﬂammation, arterial stiffness, and AGEs
is also not known. We hereby address these questions in a
12-year prospective follow-up study.
RESEARCH DESIGN AND METHODS
Study population and design. In 1993, 199 of all 242 albuminuric patients
18 years of age attending the outpatient clinic at the Steno Diabetes Center
agreed to participate and were enrolled in a prospective observational study.
Diabetic nephropathy was diagnosed according to the following criteria:
persistent macroalbuminuria (300 mg/24 h) in at least two of three previous
consecutive 24-h urine collections, presence of retinopathy, and absence of
other kidney or urinary tract disease. In addition, 192 patients with persistent
normoalbuminuria (i.e., urinary albumin excretion [UAE] rate 30 mg/24 h)
and matched for age, sex, and duration of diabetes were also enrolled as
control subjects (8). The present study refers to 339 of the original 391
patients included in the cohort; details on inclusion/exclusion criteria and
study main outcomes are depicted in a ﬂow chart (see the online appendix,
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DC1). The study was approved by the local ethics committee, in accordance
with the Helsinki Declaration, and all patients gave their informed written
consent.
Baseline investigations. Plasma levels of sRAGE were measured using a
commercially available enzyme-linked immunosorbent assay (ELISA) kit
(Quantikine; R&D systems, Minneapolis, MN) according to the manufacturer’s
protocol. Brieﬂy, a monoclonal antibody generated against the NH2-terminal
extracellular domain of human RAGE was used to capture sRAGE from
plasma. Captured sRAGE was detected with a polyclonal anti-human sRAGE
antibody. After washing, plates were incubated with streptavidin–horseradish
peroxidase, developed with appropriate substrate, and OD450 was determined
using an ELISA plate reader. Measurements were performed in duplicate and
the intra- and interassay coefﬁcient of variation (CV) values were 2 and 17.5%,
respectively.
Measurements of other biomarkers and risk factors have been described in
detail elsewhere (8,9) and in the online appendix.
Follow-up and study end points. All patients were followed up to the last
visit at the Steno Diabetes Center, until 1 September 2006 or until death (n 
82) or emigration (n  3). All patients were traced through the national
register during autumn 2006. If a patient had died before 1 September 2006,
the date of death was recorded and the primary cause of death was obtained
from the death certiﬁcate, which was reviewed by two independent observers.
Additional available information from necropsy reports was also included. All
deaths were classiﬁed as cardiovascular unless an unequivocal noncardiovas-
cular cause was established. In all patients alive at the end of follow-up,
nonfatal CVD data were retrieved from their patient ﬁles at Steno Diabetes
Center or other hospital records. The primary end point was a combination of
fatal and nonfatal CVD (i.e., myocardial infarction, percutaneous coronary
intervention, coronary bypass grafting, amputation due to ischemia, vascular
surgery for peripheral atherosclerotic disease, and stroke), and the secondary
end point was all-cause mortality.
Statistical analysis. All analyses were performed with SPSS version 15.0 for
Windows (SPSS, Chicago, IL).
Variables with a skewed distribution were loge-transformed before further
analyses. Comparisons of baseline characteristics between groups were
performed with Student’s t or 
2 tests, as appropriate. The associations
between Ln-sRAGE and study end points were investigated with Cox propor-
tional hazards regression models adjusted ﬁrst for sex, age, duration of
diabetes, case-control status, and A1C; second for other traditional cardiovas-
cular risk factors; and third for the use of renin-angiotensin-aldosterone
system inhibitors and/or other antihypertensive treatment or whether subjects
did or did not withhold their medication before baseline examinations.
Further adjustments for markers of renal dysfunction (i.e., estimated glomer-
ular ﬁltration rate [eGFRMDRD] or Ln-UAE rate), low-grade inﬂammation
(average of the z scores of Ln–interleukin-6, Ln–C-reactive protein, soluble
intracellular adhesion molecule-1 [sICAM-1], and Ln-secreted phospholipase-
A2), endothelial dysfunction (average of the z scores of soluble vascular cell
adhesion molecule-1 and sICAM-1), and arterial stiffness (i.e., pulse pressure)
were added into this model to ascertain the extent these could explain (i.e.,
attenuate the strength of) the association between Ln-sRAGE and study end
points. The cross-sectional associations between Ln-sRAGE and markers of
these pathophysiological mechanisms and AGEs [average of the z scores of
Ln-pentosidine, N
ε -(carboxymethyl)lysine, and N
ε -(carboxyethyl)lysine] were
examined with the use of linear regression analyses.
Finally, we investigated whether the associations listed above differed
between patients with normoalbuminuria versus nephropathy by adding
interaction terms between Ln-sRAGE and case-control status to our models;
whenever the P value of such interactions were 0.1, results were presented
for the two groups separately.
RESULTS
During the course of follow-up (median 12.3 years [inter-
quartile range 7.6–12.5]), 82 individuals (24.2%) died; 85
(25.1%) suffered a fatal (n  48) and/or nonfatal (n  53)
CVD event. Individuals with incident CVD events or who
had died at follow-up had at baseline higher levels of
Ln-sRAGE and a more adverse atherosclerotic risk (Table
1).
After adjustments for age, sex, case-control status, A1C,
and duration of diabetes, the incidence of fatal and non-
fatal CVD increased with a hazard ratio (HR) of 2.00 (95%
CI 1.19–3.36), and the incidence of all-cause mortality
increased with a HR of 2.44 (1.46–4.07), per unit increase
in baseline levels of Ln-sRAGE (Table 2, model 1, Fig. 1A
and B, respectively). The associations between Ln-sRAGE
and study end points were attenuated, but remained
signiﬁcant after adjustments for other CVD risk factors
and the use of medication: HR 1.90 (1.13–3.21) for fatal and
nonfatal CVD events and 2.12 (1.26–3.57) for all-cause
mortality (Table 2, models 2 and 3).
Further adjustment for eGFRMDRD attenuated the asso-
ciations between Ln-sRAGE and incident fatal and nonfa-
tal CVD as well as all-cause mortality by 28 and 14%,
respectively (Table 2, model 4). Adjustments for Ln-UAE
rate, pulse pressure, and AGEs attenuated these associa-
tions to a smaller extent, whereas adjustments for markers
of endothelial dysfunction and low-grade inﬂammation did
not (Table 2, models 5–9), despite the adverse associations
between Ln-sRAGE and these variables (Table 3).
However, the adverse associations between Ln-sRAGE
on the one hand and baseline levels of eGFRMDRD, inﬂam-
mation, endothelial dysfunction, and AGEs on the other
were stronger in individuals with nephropathy than in
those with normoalbuminuria (Table 3).
Additional analyses. We investigated the role of eGFR in
the associations between Ln-sRAGE and end points fur-
ther and found 1) that in subjects with nephropathy,
higher baseline Ln-sRAGE levels were associated with
steeper declines in eGFRMDRD as well as GFR as estimated
according to the 3.7-MBq 51Cr-EDTA method (GFREDTA)
over the course of follow-up and 2) that the decline in
(e)GFR attenuated the associations between Ln-sRAGE
and study outcomes (see the online appendix).
DISCUSSION
The main ﬁndings of this study were twofold. First, in
patients with type 1 diabetes, higher levels of plasma
sRAGE are associated with incident fatal and nonfatal
CVD as well as all-cause mortality, independently of other
‘traditional’ cardiovascular risk factors. Second, these
associations could be partially explained by sRAGE-asso-
ciated impairment in renal clearance, particularly in pa-
tients with nephropathy. Our ﬁndings are in agreement
with studies that have examined the associations of
sRAGE with CVD, but these were limited by cross-sec-
tional designs (7,10–12). This is the ﬁrst prospective study
that has investigated the associations between plasma
sRAGE and incident fatal and nonfatal CVD as well as
all-cause mortality in a large sample of individuals with
type 1 diabetes and has also addressed potential mecha-
nisms that could explain the associations observed.
We hypothesized sRAGE to act as a putative marker of
RAGE expression. The adverse associations found be-
tween sRAGE and CVD but also between sRAGE and
markers of renal and endothelial dysfunction, low-grade
inﬂammation, pulse pressure, and AGEs reported herein,
which are in agreement with others (7,10–15), supported
this hypothesis. However, sRAGE reﬂects the total pool of
soluble RAGE in plasma and thus consists of different
variants. These can result from alternative splicing (16) or
from proteolytical cleavage of the membrane-bound RAGE
(17). The exact functions of sRAGE in plasma are un-
known, but these may differ across different variants.
Indeed, several studies have reported inverse and thus
“protective” associations between endogenous secretory
RAGE (esRAGE) and (surrogate markers of) CVD (11,18–
23). We have measured the total pool of plasma sRAGE
only and therefore cannot discern whether the different
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associations with study outcomes. In addition, the extent
to which levels of (e)sRAGE in plasma reﬂect the local
concentrations and have the same effects as in tissues
need to be further clariﬁed.
The associations of sRAGE with CVD and all-cause
mortality were attenuated when further adjusted for base-
line eGFR, the former association being no longer statis-
tically signiﬁcant. However, this adjustment explained
only 28% of the increased CVD risk associated with higher
sRAGE. In addition, independent associations of both
sRAGE and creatinine with CVD have been reported in
individuals with diabetes (10). Furthermore, we found that
sRAGE contributed to an accelerated decline in GFR, as
estimated by eGFRMDRD or by GFREDTA in subjects with
diabetic nephropathy. This is in line with a recent study in
which sRAGE was inversely associated with changes in
eGFR in the course of 1 year of follow-up in a large
population of elderly women (24). These ﬁndings support
the hypothesis of renal dysfunction being one of the
intermediate factors linking sRAGE (as a reﬂection of
RAGE expression) to vascular complications. However,
we cannot discard the alternative (or concomitant)
possibility, i.e., that baseline sRAGE levels may have
been elevated as a consequence of impaired renal
clearance. Indeed, our data also support this possibility;
speciﬁcally, the association between higher baseline
eGFR (per 10 ml/min per 1.73 m
2) and incident CVD (HR
0.89 [95% CI 0.78–1.00]) was attenuated by 24% when
further adjusted for Ln-sRAGE (to HR 0.92 [95% CI
0.81–1.04]). These observations reﬂect the interrelation-
ships between sRAGE and eGFR at baseline, the exact
directions of which we cannot fully unravel in the
present study. Nevertheless, and altogether, these ob-
servations support the view that higher sRAGE levels,
due to, but also to a great extent independent of,
impaired GFR, are positively associated with CVD and
all-cause mortality. Further studies with repeated data
TABLE 1
Baseline characteristics according to the occurrence of cardiovascular events and death during follow-up
Fatal or
nonfatal CVD
event (n  85)
No CVD event
(n  254) P
Patients dead
at follow-up
(n  82)
Patients alive
at follow-up
(n  257) P
Sex (% M/F) 61/39 60/40 0.901 68/32 58/42 0.156
Age (years) 44.7  9.0 40.3  9.6 0.001 45.5  9.9 40.1  9.2 0.001
Duration of diabetes (years) 30.7  8.8 26.8  7.5 0.001 30.3  10.0 27.0  7.1 0.006
Nephropathy (%) 75 41 0.001 78 41 0.001
Retinopathy: no/simplex/
proliferative (%) 8/37/55 21/45/34 0.001 6/37/57 21/45/34 0.001
A1C (%) 9.5  1.5 8.9  1.4 0.001 9.6  1.5 8.8  1.4 0.001
Total cholesterol (mmol/l) 5.70  1.10 4.99  1.12 0.001 5.80  1.13 4.97  1.10 0.001
HDL (mmol/l) 1.43  0.42 1.55  0.55 0.033 1.52  0.48 1.52  0.54 0.961
Triglycerides (mmol/l) 1.24 (0.93–1.70) 0.81 (0.63–1.19) 0.001 1.28 (0.90–1.66) 0.81 (0.64–1.16) 0.001
Creatinine (mol/l) 104 (77–150) 80 (71–92) 0.001 105 (78–147) 79 (72–92) 0.001
Estimated GFRMDRD
(ml/min/1.73 m
2) 65.5  29.1 86.8  21.1 0.001 65.5  27.8 86.6  21.9 0.001
GFREDTA (ml/min/1.73 m
2)* 60.8  31.3* 84.7  30.1* 0.001 60.6  30.6* 84.6  30.5* 0.001
UAE rate (mg/24 h) 644 (33–1,940) 17 (7–525) 0.001 720 (82–2,012) 16 (7–468) 0.001
Systolic blood pressure (mmHg) 157  24 136  20 0.001 159  24 136  19 0.001
Diastolic blood pressure (mmHg) 85  13 79  12 0.001 86  14 79  11 0.001
Mean arterial pressure (mmHg) 109  15 98  13 0.001 111  15 98  13 0.001
Pulse pressure (mmHg) 73  21 57  15 0.001 73  21 57  15 0.001
Renin-angiotensin-aldosterone
system inhibitors (%) 51 20 0.001 50 20 0.001
Other antihypertensive agents (%) 64 28 0.001 68 27 0.001
Lipid-lowering agents (%) 0 0 — 0 0 —
Continuation of medication (%) 32 10 0.001 30 11 0.001
Smoking: never/former/current (%) 28/19/53 37/17/46 0.513 26/17/57 38/18/44 0.085
Soluble RAGE (ng/ml) 1.02 (0.80–1.41) 0.97 (0.72–1.37) 0.057 1.12 (0.83–1.53) 0.96 (0.72–1.33) 0.001
N
-(carboxymethyl)lysine (mol/l) 3.60  1.12 3.54  0.84 0.634 3.56  1.32 3.55  0.75 0.967
N
-(carboxyethyl)lysine (mol/l) 1.02  0.28 0.92  0.19 0.004 1.03  0.30 0.92  0.18 0.003
Pentosidine (pmol/mg) 49.3 (35.7–71.8) 40.8 (34.0–49.0) 0.001 51.8 (34.2–73.1) 41.0 (34.2–48.9) 0.001
C-reactive protein (mg/l) 1.59 (0.64–3.22) 0.96 (0.41–2.09) 0.008 1.42 (0.59–3.26) 1.02 (0.44–2.16) 0.021
Secreted phospholipase A2 (g/ml) 4.40 (2.80–7.00) 4.00 (2.70–6.23) 0.329 4.05 (2.80–6.55) 4.00 (2.70–6.55) 0.948
Interleukin-6 (pg/ml) 2.18 (1.52–3.45) 1.49 (0.99–2.35) 0.001 2.42 (1.75–3.89) 1.44 (1.00–2.21) 0.001
Soluble vascular cell adhesion
molecule-1 (sVCAM-1) (ng/ml) 1,045  269 984  346 0.141 1,100  346 967  318 0.001
Soluble intracellular adhesion
molecule-1 (sICAM-1) (ng/ml) 771  258 726  272 0.182 805  286 715  260 0.008
Low-grade inﬂammation score 0.21  0.57 	0.07  0.68 0.001 0.23  0.65 	0.07  0.65 0.001
Endothelial dysfunction score 0.13  0.70 	0.04  0.81 0.074 0.28  0.85 	0.09  0.75 0.001
AGEs score 0.26  1.17 	0.09  0.79 0.012 0.27  1.32 	0.08  0.72 0.024
Data are means  SD, medians (interquartile range), or percent. *Data of GFREDTA were only available in patients with diabetic nephropathy
(n  165).
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temporal order of these associations.
There are limitations to our study. Samples for analyses
of sRAGE and other biomarkers were taken at baseline
only, which impedes evaluation of the impact of changes
in these variables on study outcomes. In addition, the
relatively high interassay CV in the measurement of
plasma sRAGE, and the potential misclassiﬁcation of
nonspeciﬁc mortality as CVD-related mortality may have
introduced nondifferential biases, in which case the esti-
mates reported herein may have been underestimated.
However, we cannot discard the possibility that possible
underreporting of nonfatal CVD introduced some differen-
tial bias affecting our results. Finally, although our ﬁndings
did not suggest strong mediating effects of endothelial
dysfunction, low-grade inﬂammation, arterial stiffness, and
AGEs in the associations between sRAGE and study
outcomes, we cannot fully exclude their potential mediat-
ing role due to the use of a selection of markers represent-
ing these processes.
In conclusion, higher plasma sRAGE levels, as a reﬂec-
tion of RAGE expression, are associated with incident
fatal and nonfatal CVD as well as all-cause mortality in
type 1 diabetes, and this may partially be explained by
sRAGE-associated renal dysfunction in patients with
nephropathy.
TABLE 2
Associations between plasma Ln-sRAGE and incident CVD events and all-cause mortality in the whole study population (n  339)
Fatal and nonfatal CVD All-cause mortality
HR* 95% CI P HR* 95% CI P
Model: adjustments
1: age, sex, A1C, case-control status, and duration
of diabetes 2.00 1.19–3.36 0.009 2.44 1.46–4.07 0.001
2: model 1 
 mean arterial pressure, smoking
status, and total cholesterol 1.87 1.13–3.08 0.014 2.29 1.40–3.76 0.001
3a: model 2 
 renin-angiotensin-aldosterone
system inhibitors agents 1.85 1.12–3.04 0.016 2.33 1.42–3.83 0.001
3b: model 2 
 other antihypertensive agents 1.68 1.01–2.81 0.048 1.97 1.18–3.28 0.010
3c: model 2 
 continuation of medication use at
baseline examination 1.98 1.19–3.28 0.009 2.31 1.40–3.81 0.001
3: model 3a, 3b, and 3c 1.90 1.13–3.21 0.016 2.12 1.26–3.57 0.005
4: model 3 
 eGFRMDRD 1.59 0.91–2.77 0.106 1.90 1.09–3.31 0.023
5: model 3 
 Ln-UAE 1.74 1.03–2.94 0.040 2.00 1.18–3.39 0.010
6: model 3 
 inﬂammatory score 1.89 1.12–3.19 0.018 2.12 1.26–3.57 0.005
7: model 3 
 endothelial dysfunction score 1.92 1.13–3.26 0.016 2.04 1.20–3.44 0.008
8: model 3 
 pulse pressure 1.67 0.98–2.87 0.059 1.91 1.12–3.25 0.017
9: model 3 
 AGEs score 1.74 1.02–2.98 0.042 1.98 1.16–3.38 0.012
*Hazard ratio for CVD morbidity and mortality or all-cause mortality per each unit increase in Ln-sRAGE levels at baseline.
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FIG. 1. Cumulative hazard for CVD morbidity and mortality (A) as well as all-cause mortality (B) across tertiles of plasma sRAGE. Data are
adjusted for age, sex, case-control status, duration of diabetes, and A1C. Compared with patients in the lowest tertile of sRAGE, those in the
middle and highest tertiles had increased risk for fatal and nonfatal CVD (HR 1.33 [95% CI 0.76–2.31] and 1.78 [1.03–3.06], respectively, P for
trend 0.038) and all-cause mortality (1.31 [0.73–2.38] and 2.04 [1.17–3.55], respectively, P for trend  0.010).
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Baseline eGFRMDRD* 1 	0.28 	0.36 to 	0.20 0.001 	0.04 	0.15 to 0.06 0.422 	0.41 	0.53 to 	0.30 0.001
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and continuation of medication at baseline examination. Symbols indicate signiﬁcant interaction between sRAGE and case-control status,
and therefore associations are also presented for each group separately (speciﬁcally, *P  0.001, †P  0.044, ‡P  0.068, and §P  0.021).
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